Novilytic

Role(s)	• Novilytic is a molecular recognition company that utilizes nanotechnology to monitor the quality of lifesaving medicines. Our product, the Proteometer, is for pharmaceutical chemists and engineers who develop and produce bad chemistry because they cannot gain process data in real-time. Unlike the 40-year-old technology they use today that take 12 - 24 hours to report, the Proteometer utilizes patented technology to provide answers every 10 minutes. • The impact the Proteometer will play on pharmaceutical manufacturing is very disruptive. Each batch of protein-based drugs costs $20M to produce. It is well documented that 40%-60% of this cost is in purification because they do not gain molecular data in real-time. Our nanotechnology solves this issue, reducing the cost of pharmaceuticals and increasing access to life-saving drugs for all.
Mission	Making life-saving medications less expensive and available to more people.
History	2018 – Novilytic patents the MASC technology, using nano particles for pharmaceutical analysis 2020 – Company’s first product prototype (the Proteometer aka “proteoform meter”) 2021 – Company grows from 3 to 10 employees to hasten product development and commercialization efforts 2021 – Company applies for additional patents 2022 (May) Completed $1.6M Seed Funding Round September 2022 – IEDC grant received December 2022 – Pilot test at instrument companies and major CDMOs begin February 2023 – Nominated for a TechPoint Mira Award in the category of Product Innovation of the Year February 2023 – Launch of 1st Product, Proteometer-L Kit Spring 2024 - J&J Pharmaceuticals presents peer-reviewed paper at industry's largest analytical conference Summer 2023 – Journal of Analytical Chemistry publishes cover story and article on Novilytic technology Q1 2024 - First major distributor listing and $600K contract with major pharma company
Org	9 full-time employees with an Orr Fellow and TechPoint Xtern scheduled to start in June. Leadership: • Paul C. Dreier, BSc., MBA – CEO • Fred E. Regnier, Ph.D. – CTO • Timothy E. Woenker, BSc. – COO • Jiri Adamec, Ph.D. – Co-founder and Technical Counsel
Board	Paul C. Dreier, BSc., MBA – CEO Fred E. Regnier, Ph.D. – CTO Timothy E. Woenker, BSc. – COO Jiri Adamec, Ph.D. – Co-Founder and Technical Counsel Mike Bolinder - Bio Crossroads (& Elevate Ventures)
Finance	Projected revenue 2023: $2,405,108 Projected revenue 2024: $19,217,493 Projected revenue 2025: $70,930,375
Data Source	N/A
Data Access	N/A
Tech Capabilities	• The Proteometer is a Hard Tech product designed for plug-and-play connection to >253,000 instruments already present in medicine-making laboratories. • Our laboratories include multiple analytical instruments, chemistry-related sensors, and devices, as well as the software that captures and processes all that data. • The Novilytic Team includes multiple Ph.D. and Masters level analytical chemists, biochemistry engineers, and other scientists
Projects	Proteometer-L Kit – Launching February 28, 2023 Patented consumables kit that solves the largest issue in pharmaceutical processing – Real-Time Molecular Recognition and Quantification This “L” version addresses the effects of aggregation, one of four major target issues per multiple Pharma and CDMO customers Proteometer-UFT Kit - Launching Q1 2024 Runs at-line titer measurement of mAbs in less than 90 seconds Proteometer-CV Kit – Launching Summer 2024 This “CV” version addresses the effects of charge variants, one of four major target issues per multiple Pharma and CDMO customers Proteometer-O2 Kit – Launching Winter 2024 This “CV” version addresses the effects of oxidation, one of four major target issues per multiple Pharma and CDMO customers Longer term : Proteometer-PD1 For efficacy and antibody activity Proteometer-LF For continuous processes manufacturing of pharmaceuticals Proteometer-LA For animal-based pharmaceuticals Proteometer-LDC For drug conjugated antibodies Additional customer requests
Future Focus	Novilytic plans to release additional kits that are assay patented consumables kit that solves the largest issue in pharmaceutical development and processing – Real Time Molecular Recognition and Quantification
Talent Development	• We have strong partnerships with The Orr Fellowship and TechPoint that we hope to continue utilizing for interns and entry-level employees • Many of our employees continue their education through industry certificate. • We are in the early stages of developing a mentorship program
Data Sharing Agreements	• National Institute for Innovation in Manufacturing Pharmaceuticals ("NIIMBL" - NIH & Big Pharma manufacturing consortium) The Antibody Society (Consortium of major pharmaceutical companies and scientists) • Multiple major pharmaceutical and CDMO organizations • Multiple very large instrument companies who will sell the Proteometer for use with their instruments (in process) • Purdue University / PRF
Programs/ Publications	Literature \| Novilytic

Novilytic, LLC.
1281 Win Hentschel Blvd, West Lafayette, IN 47906 Novilytic.com info@novilytic.com	Private Sector